Marisol Soengas

List of Publications by Year
in descending order

67 papers	12,321 citations	147801 31 h-index	118850 62 g-index
70 all docs	70 docs citations	70 times ranked	21062 citing authors

#	Article	IF	Citations
1	Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nature Communications, 2022, 13, 2760.	12.8	19
2	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53
3	Melanoma models for the next generation of therapies. Cancer Cell, 2021, 39, 610-631.	16.8	90
4	Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles. Advanced Drug Delivery Reviews, 2021, 175, 113833.	13.7	15
5	Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Molecular Medicine, 2021, 13, e12924.	6.9	1
6	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nature Medicine, 2020, 26, 1865-1877.	30.7	62
7	Lymph: (Fe)rrying Melanoma to Safety. Cancer Cell, 2020, 38, 446-448.	16.8	4
8	KLF9-dependent ROS regulate melanoma progression in stage-specific manner. Oncogene, 2019, 38, 3585-3597.	5.9	49
9	p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell, 2019, 35, 46-63.e10.	16.8	50
10	<scp>DEK</scp> oncogene is overexpressed during melanoma progression. Pigment Cell and Melanoma Research, 2017, 30, 194-202.	3.3	19
11	TYRP1 mRNA goes fishing for miRNAs in melanoma. Nature Cell Biology, 2017, 19, 1311-1312.	10.3	12
12	Location, Location, Location: Spatio-Temporal Cues That Define the Cell of Origin in Melanoma. Cell Stem Cell, 2017, 21, 559-561.	11.1	7
13	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research, 2017, 77, 5873-5885.	0.9	26
14	Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. Nature, 2017, 546, 676-680.	27.8	123
15	Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1. Nature Communications, 2017, 8, 2249.	12.8	22
16	TRANSAUTOPHAGY: European network for multidisciplinary research and translation of autophagy knowledge. Autophagy, 2016, 12, 614-617.	9.1	2
17	Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies. FEBS Journal, 2016, 283, 25-38.	4.7	22
18	Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of<i>ATG5</i>. Autophagy, 2016, 12, 1776-1790.	9.1	31

#	Article	IF	Citations
19	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
20	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. Nature Communications, 2016, 7, 13418.	12.8	46
21	UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis. Cancer Cell, 2016, 30, 694-707.	16.8	131
22	Evaluation of the antiproliferative, proapoptotic, and antiangiogenic effects of a double-stranded RNA mimic complexed with polycations inÂan experimental mouse model ofÂleiomyoma. Fertility and Sterility, 2016, 105, 529-538.	1.0	3
23	The nuclear corepressor 1 and the thyroid hormone receptor Î² suppress breast tumor lymphangiogenesis. Oncotarget, 2016, 7, 78971-78984.	1.8	15
24	Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy. Current Pharmaceutical Design, 2016, 22, 6234-6250.	1.9	19
25	Let's make it happen: for gender equality in science!. Pigment Cell and Melanoma Research, 2015, 28, 641-642.	3.3	0
26	Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations inÂanÂexperimental mouse model ofÂendometriosis. Fertility and Sterility, 2015, 104, 1310-1318.	1.0	7
27	Hyperactivated endolysosomal trafficking in melanoma. Oncotarget, 2015, 6, 2583-2584.	1.8	12
28	RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development. Oncotarget, 2015, 6, 11848-11862.	1.8	19
29	DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer, 2014, 14, 965.	2.6	24
30	Unmet needs in melanoma research. Pigment Cell and Melanoma Research, 2014, 27, 1003-1003.	3.3	2
31	RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway. Cancer Cell, 2014, 26, 61-76.	16.8	86
32	BO-110, a dsRNA-Based Anticancer Agent. Advances in Delivery Science and Technology, 2014, , 453-470.	0.4	0
33	Ze'ev Ronai. Pigment Cell and Melanoma Research, 2013, 26, 924-924.	3.3	0
34	Mitophagy or how to control the Jekyll and Hyde embedded in mitochondrial metabolism: implications for melanoma progression and drug resistance. Pigment Cell and Melanoma Research, 2012, 25, 721-731.	3.3	16
35	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
36	Proteasome inhibition and ROS generation by 4â€nerolidylcatechol induces melanoma cell death. Pigment Cell and Melanoma Research, 2012, 25, 354-369.	3.3	32

#	Article	IF	Citations
37	Artificial skin in perspective: concepts and applications. Pigment Cell and Melanoma Research, 2011, 24, 35-50.	3.3	185
38	The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell and Melanoma Research, 2011, 24, 1116-1132.	3.3	21
39	Control of Tumorigenesis and Chemoresistance by the DEK Oncogene. Clinical Cancer Research, 2010, 16, 2932-2938.	7.0	71
40	Self-killing of melanoma cells by cytosolic delivery of dsRNA: Wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. Autophagy, 2010, 6, 148-150.	9.1	20
41	Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene. Cancer Research, 2009, 69, 6405-6413.	0.9	127
42	ROC1/RBX1 E3 Ubiquitin Ligase Silencing Suppresses Tumor Cell Growth via Sequential Induction of G2-M Arrest, Apoptosis, and Senescence. Cancer Research, 2009, 69, 4974-4982.	0.9	106
43	Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma. Cancer Research, 2009, 69, 1985-1994.	0.9	70
44	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. Cancer Cell, 2009, 16, 103-114.	16.8	163
45	Ins and outs of tumour control. Nature, 2008, 454, 586-587.	27.8	4
46	Comment on â€œAbsence of Senescence-Associated Î²-Galactosidase Activity in Human Melanocytic Nevi In Vivoâ€. Journal of Investigative Dermatology, 2008, 128, 1582-1583.	0.7	15
47	Looping tumor suppression. Pigment Cell and Melanoma Research, 2008, 21, 592-593.	3.3	0
48	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. Cancer Biology and Therapy, 2008, 7, 767-776.	3.4	17
49	Activation of p53 Signaling Is Synergistically Enhanced by Bcl-2 Inhibition through Induction of Noxa and Bak/Bax Heterodimers Resulting in Apoptosis of AML Stem Cells. Blood, 2008, 112, 2940-2940.	1.4	0
50	An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells. Cancer Research, 2007, 67, 209-217.	0.9	224
51	Bcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth. Cancer Research, 2007, 67, 9685-9693.	0.9	94
52	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19488-19493.	7.1	171
53	BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Research, 2006, 16, 267-273.	1.2	213
54	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nature Cell Biology, 2006, 8, 1053-1063.	10.3	296

#	Article	IF	Citations
55	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.	16.8	921
56	A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinaseâ€"Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species. Cancer Research, 2006, 66, 11348-11359.	0.9	138
57	Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib. Journal of Biological Chemistry, 2006, 281, 1107-1118.	3.4	41
58	Proteasome Inhibitor PS-341 Induces Apoptosis in Cisplatin-resistant Squamous Cell Carcinoma Cells by Induction of Noxa. Journal of Biological Chemistry, 2006, 281, 31440-31447.	3.4	111
59	Proteasome Inhibitor PS-341 Induces Apoptosis in Cisplatin-resistant Squamous Cell Carcinoma Cells by Induction of Noxa. Journal of Biological Chemistry, 2006, 281, 31440-31447.	3.4	31
60	BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature, 2005, 436, 720-724.	27.8	1,933
61	Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications. Cancer Research, 2005, 65, 6294-6304.	0.9	208
62	Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22, 3138-3151.	5.9	757
63	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207-211.	27.8	901
64	p53 and p73: seeing double?. Nature Genetics, 2000, 26, 391-392.	21.4	13
65	Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo. Cell, 1998, 94, 339-352.	28.9	1,224
66	Structural Features of Ï†29 Single-stranded DNA-binding Protein. Journal of Biological Chemistry, 1997, 272, 303-310.	3.4	12
67	Structural Features of Ï†29 Single-stranded DNA-binding Protein. Journal of Biological Chemistry, 1997, 272, 295-302.	3.4	8